Pharma & Healthcare
Antibacterial (Drug) Resistance - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Sep 18, 24
- ID: 552856
- Pages: 161
- Figures: 270
- Views: 1
Antibacterial drug resistance is the process that bacteria use to tolerate and overcome the effects of antibiotic drugs. Resistance can arise through mutations or can be acquired from other bacteria through plasmids.
The global market for Antibacterial (Drug) Resistance was estimated to be worth US$ 8122 million in 2023 and is forecast to a readjusted size of US$ 11740 million by 2030 with a CAGR of 5.3% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antibacterial (Drug) Resistance, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Antibacterial (Drug) Resistance by region & country, by Type, and by Indication.
The Antibacterial (Drug) Resistance market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibacterial (Drug) Resistance.
Market Segmentation
By Company
Melinta Therapeutics
Allergan
Merck
Abbott Laboratories
Pfizer
GSK
PENDOPHARM
Absynth Biologics
Achaogen
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO
Segment by Type:
Telavancin (Vibativ)
Ceftaroline Fosamil (Teflaro/ Zinforo)
Fidaxomicin (Dificid / Dificlir)
Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Dalbavancin (Dalvance/ Xydalba)
Tedizolid Phosphate (Sivextro)
Oritavancin (Orbactiv/ Nuvocid)
Ceftolozane-Tazobactam (Zerbaxa)
Ceftazidime-Avibactam (Avycaz/ Zavicefta)
PHASE III DRUGS
Segment by Indication
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Clostridium Difficile Infections (CDI)
Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Antibacterial (Drug) Resistance manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Indication, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Antibacterial (Drug) Resistance in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Antibacterial (Drug) Resistance in country level. It provides sigmate data by Type, and by Indication for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Antibacterial (Drug) Resistance was estimated to be worth US$ 8122 million in 2023 and is forecast to a readjusted size of US$ 11740 million by 2030 with a CAGR of 5.3% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antibacterial (Drug) Resistance, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Antibacterial (Drug) Resistance by region & country, by Type, and by Indication.
The Antibacterial (Drug) Resistance market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibacterial (Drug) Resistance.
Market Segmentation
By Company
Melinta Therapeutics
Allergan
Merck
Abbott Laboratories
Pfizer
GSK
PENDOPHARM
Absynth Biologics
Achaogen
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO
Segment by Type:
Telavancin (Vibativ)
Ceftaroline Fosamil (Teflaro/ Zinforo)
Fidaxomicin (Dificid / Dificlir)
Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Dalbavancin (Dalvance/ Xydalba)
Tedizolid Phosphate (Sivextro)
Oritavancin (Orbactiv/ Nuvocid)
Ceftolozane-Tazobactam (Zerbaxa)
Ceftazidime-Avibactam (Avycaz/ Zavicefta)
PHASE III DRUGS
Segment by Indication
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Clostridium Difficile Infections (CDI)
Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Antibacterial (Drug) Resistance manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Indication, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Antibacterial (Drug) Resistance in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Antibacterial (Drug) Resistance in country level. It provides sigmate data by Type, and by Indication for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Antibacterial (Drug) Resistance Product Introduction
1.2 Global Antibacterial (Drug) Resistance Market Size Forecast
1.2.1 Global Antibacterial (Drug) Resistance Sales Value (2019-2030)
1.2.2 Global Antibacterial (Drug) Resistance Sales Volume (2019-2030)
1.2.3 Global Antibacterial (Drug) Resistance Sales Price (2019-2030)
1.3 Antibacterial (Drug) Resistance Market Trends & Drivers
1.3.1 Antibacterial (Drug) Resistance Industry Trends
1.3.2 Antibacterial (Drug) Resistance Market Drivers & Opportunity
1.3.3 Antibacterial (Drug) Resistance Market Challenges
1.3.4 Antibacterial (Drug) Resistance Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Antibacterial (Drug) Resistance Players Revenue Ranking (2023)
2.2 Global Antibacterial (Drug) Resistance Revenue by Company (2019-2024)
2.3 Global Antibacterial (Drug) Resistance Players Sales Volume Ranking (2023)
2.4 Global Antibacterial (Drug) Resistance Sales Volume by Company Players (2019-2024)
2.5 Global Antibacterial (Drug) Resistance Average Price by Company (2019-2024)
2.6 Key Manufacturers Antibacterial (Drug) Resistance Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Antibacterial (Drug) Resistance Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Antibacterial (Drug) Resistance
2.9 Antibacterial (Drug) Resistance Market Competitive Analysis
2.9.1 Antibacterial (Drug) Resistance Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Antibacterial (Drug) Resistance Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibacterial (Drug) Resistance as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Telavancin (Vibativ)
3.1.2 Ceftaroline Fosamil (Teflaro/ Zinforo)
3.1.3 Fidaxomicin (Dificid / Dificlir)
3.1.4 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
3.1.5 Dalbavancin (Dalvance/ Xydalba)
3.1.6 Tedizolid Phosphate (Sivextro)
3.1.7 Oritavancin (Orbactiv/ Nuvocid)
3.1.8 Ceftolozane-Tazobactam (Zerbaxa)
3.1.9 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
3.1.10 PHASE III DRUGS
3.2 Global Antibacterial (Drug) Resistance Sales Value by Type
3.2.1 Global Antibacterial (Drug) Resistance Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Antibacterial (Drug) Resistance Sales Value, by Type (2019-2030)
3.2.3 Global Antibacterial (Drug) Resistance Sales Value, by Type (%) (2019-2030)
3.3 Global Antibacterial (Drug) Resistance Sales Volume by Type
3.3.1 Global Antibacterial (Drug) Resistance Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Antibacterial (Drug) Resistance Sales Volume, by Type (2019-2030)
3.3.3 Global Antibacterial (Drug) Resistance Sales Volume, by Type (%) (2019-2030)
3.4 Global Antibacterial (Drug) Resistance Average Price by Type (2019-2030)
4 Segmentation by Indication
4.1 Introduction by Indication
4.1.1 Complicated Urinary Tract Infection (CUTI)
4.1.2 Complicated Intra-Abdominal Infections (CIAI)
4.1.3 Blood Stream Infections (BSI)
4.1.4 Clostridium Difficile Infections (CDI)
4.1.5 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
4.1.6 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
4.1.7 Community Acquired Bacterial Pneumonia (CABP)
4.2 Global Antibacterial (Drug) Resistance Sales Value by Indication
4.2.1 Global Antibacterial (Drug) Resistance Sales Value by Indication (2019 VS 2023 VS 2030)
4.2.2 Global Antibacterial (Drug) Resistance Sales Value, by Indication (2019-2030)
4.2.3 Global Antibacterial (Drug) Resistance Sales Value, by Indication (%) (2019-2030)
4.3 Global Antibacterial (Drug) Resistance Sales Volume by Indication
4.3.1 Global Antibacterial (Drug) Resistance Sales Volume by Indication (2019 VS 2023 VS 2030)
4.3.2 Global Antibacterial (Drug) Resistance Sales Volume, by Indication (2019-2030)
4.3.3 Global Antibacterial (Drug) Resistance Sales Volume, by Indication (%) (2019-2030)
4.4 Global Antibacterial (Drug) Resistance Average Price by Indication (2019-2030)
5 Segmentation by Region
5.1 Global Antibacterial (Drug) Resistance Sales Value by Region
5.1.1 Global Antibacterial (Drug) Resistance Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Antibacterial (Drug) Resistance Sales Value by Region (2019-2024)
5.1.3 Global Antibacterial (Drug) Resistance Sales Value by Region (2025-2030)
5.1.4 Global Antibacterial (Drug) Resistance Sales Value by Region (%), (2019-2030)
5.2 Global Antibacterial (Drug) Resistance Sales Volume by Region
5.2.1 Global Antibacterial (Drug) Resistance Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Antibacterial (Drug) Resistance Sales Volume by Region (2019-2024)
5.2.3 Global Antibacterial (Drug) Resistance Sales Volume by Region (2025-2030)
5.2.4 Global Antibacterial (Drug) Resistance Sales Volume by Region (%), (2019-2030)
5.3 Global Antibacterial (Drug) Resistance Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Antibacterial (Drug) Resistance Sales Value, 2019-2030
5.4.2 North America Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Antibacterial (Drug) Resistance Sales Value, 2019-2030
5.5.2 Europe Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Antibacterial (Drug) Resistance Sales Value, 2019-2030
5.6.2 Asia Pacific Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Antibacterial (Drug) Resistance Sales Value, 2019-2030
5.7.2 South America Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Antibacterial (Drug) Resistance Sales Value, 2019-2030
5.8.2 Middle East & Africa Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Antibacterial (Drug) Resistance Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Antibacterial (Drug) Resistance Sales Value
6.2.1 Key Countries/Regions Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.2.2 Key Countries/Regions Antibacterial (Drug) Resistance Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.3.2 United States Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
6.4 Europe
6.4.1 Europe Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.4.2 Europe Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
6.5 China
6.5.1 China Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.5.2 China Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.5.3 China Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
6.6 Japan
6.6.1 Japan Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.6.2 Japan Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.7.2 South Korea Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.8.2 Southeast Asia Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
6.9 India
6.9.1 India Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.9.2 India Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.9.3 India Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
7 Company Profiles
7.1 Melinta Therapeutics
7.1.1 Melinta Therapeutics Company Information
7.1.2 Melinta Therapeutics Introduction and Business Overview
7.1.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Melinta Therapeutics Antibacterial (Drug) Resistance Product Offerings
7.1.5 Melinta Therapeutics Recent Development
7.2 Allergan
7.2.1 Allergan Company Information
7.2.2 Allergan Introduction and Business Overview
7.2.3 Allergan Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Allergan Antibacterial (Drug) Resistance Product Offerings
7.2.5 Allergan Recent Development
7.3 Merck
7.3.1 Merck Company Information
7.3.2 Merck Introduction and Business Overview
7.3.3 Merck Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Merck Antibacterial (Drug) Resistance Product Offerings
7.3.5 Merck Recent Development
7.4 Abbott Laboratories
7.4.1 Abbott Laboratories Company Information
7.4.2 Abbott Laboratories Introduction and Business Overview
7.4.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Abbott Laboratories Antibacterial (Drug) Resistance Product Offerings
7.4.5 Abbott Laboratories Recent Development
7.5 Pfizer
7.5.1 Pfizer Company Information
7.5.2 Pfizer Introduction and Business Overview
7.5.3 Pfizer Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Pfizer Antibacterial (Drug) Resistance Product Offerings
7.5.5 Pfizer Recent Development
7.6 GSK
7.6.1 GSK Company Information
7.6.2 GSK Introduction and Business Overview
7.6.3 GSK Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.6.4 GSK Antibacterial (Drug) Resistance Product Offerings
7.6.5 GSK Recent Development
7.7 PENDOPHARM
7.7.1 PENDOPHARM Company Information
7.7.2 PENDOPHARM Introduction and Business Overview
7.7.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.7.4 PENDOPHARM Antibacterial (Drug) Resistance Product Offerings
7.7.5 PENDOPHARM Recent Development
7.8 Absynth Biologics
7.8.1 Absynth Biologics Company Information
7.8.2 Absynth Biologics Introduction and Business Overview
7.8.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Absynth Biologics Antibacterial (Drug) Resistance Product Offerings
7.8.5 Absynth Biologics Recent Development
7.9 Achaogen
7.9.1 Achaogen Company Information
7.9.2 Achaogen Introduction and Business Overview
7.9.3 Achaogen Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Achaogen Antibacterial (Drug) Resistance Product Offerings
7.9.5 Achaogen Recent Development
7.10 Acino Holdings
7.10.1 Acino Holdings Company Information
7.10.2 Acino Holdings Introduction and Business Overview
7.10.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Acino Holdings Antibacterial (Drug) Resistance Product Offerings
7.10.5 Acino Holdings Recent Development
7.11 Aventis Pharma
7.11.1 Aventis Pharma Company Information
7.11.2 Aventis Pharma Introduction and Business Overview
7.11.3 Aventis Pharma Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Aventis Pharma Antibacterial (Drug) Resistance Product Offerings
7.11.5 Aventis Pharma Recent Development
7.12 Austell Laboratories
7.12.1 Austell Laboratories Company Information
7.12.2 Austell Laboratories Introduction and Business Overview
7.12.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Austell Laboratories Antibacterial (Drug) Resistance Product Offerings
7.12.5 Austell Laboratories Recent Development
7.13 Assembly Biosciences
7.13.1 Assembly Biosciences Company Information
7.13.2 Assembly Biosciences Introduction and Business Overview
7.13.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Assembly Biosciences Antibacterial (Drug) Resistance Product Offerings
7.13.5 Assembly Biosciences Recent Development
7.14 Arpida
7.14.1 Arpida Company Information
7.14.2 Arpida Introduction and Business Overview
7.14.3 Arpida Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Arpida Antibacterial (Drug) Resistance Product Offerings
7.14.5 Arpida Recent Development
7.15 Demuris
7.15.1 Demuris Company Information
7.15.2 Demuris Introduction and Business Overview
7.15.3 Demuris Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Demuris Antibacterial (Drug) Resistance Product Offerings
7.15.5 Demuris Recent Development
7.16 Evolva Holding
7.16.1 Evolva Holding Company Information
7.16.2 Evolva Holding Introduction and Business Overview
7.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Evolva Holding Antibacterial (Drug) Resistance Product Offerings
7.16.5 Evolva Holding Recent Development
7.17 ContraFect
7.17.1 ContraFect Company Information
7.17.2 ContraFect Introduction and Business Overview
7.17.3 ContraFect Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.17.4 ContraFect Antibacterial (Drug) Resistance Product Offerings
7.17.5 ContraFect Recent Development
7.18 Cerexa
7.18.1 Cerexa Company Information
7.18.2 Cerexa Introduction and Business Overview
7.18.3 Cerexa Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Cerexa Antibacterial (Drug) Resistance Product Offerings
7.18.5 Cerexa Recent Development
7.19 InterMune
7.19.1 InterMune Company Information
7.19.2 InterMune Introduction and Business Overview
7.19.3 InterMune Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.19.4 InterMune Antibacterial (Drug) Resistance Product Offerings
7.19.5 InterMune Recent Development
7.20 Isis Pharmaceuticals
7.20.1 Isis Pharmaceuticals Company Information
7.20.2 Isis Pharmaceuticals Introduction and Business Overview
7.20.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.20.4 Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Offerings
7.20.5 Isis Pharmaceuticals Recent Development
7.21 Lyndra
7.21.1 Lyndra Company Information
7.21.2 Lyndra Introduction and Business Overview
7.21.3 Lyndra Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.21.4 Lyndra Antibacterial (Drug) Resistance Product Offerings
7.21.5 Lyndra Recent Development
7.22 Microbecide
7.22.1 Microbecide Company Information
7.22.2 Microbecide Introduction and Business Overview
7.22.3 Microbecide Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.22.4 Microbecide Antibacterial (Drug) Resistance Product Offerings
7.22.5 Microbecide Recent Development
7.23 Morphochem
7.23.1 Morphochem Company Information
7.23.2 Morphochem Introduction and Business Overview
7.23.3 Morphochem Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.23.4 Morphochem Antibacterial (Drug) Resistance Product Offerings
7.23.5 Morphochem Recent Development
7.24 Nabriva Therapeutics
7.24.1 Nabriva Therapeutics Company Information
7.24.2 Nabriva Therapeutics Introduction and Business Overview
7.24.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.24.4 Nabriva Therapeutics Antibacterial (Drug) Resistance Product Offerings
7.24.5 Nabriva Therapeutics Recent Development
7.25 NanoSafe Coatings
7.25.1 NanoSafe Coatings Company Information
7.25.2 NanoSafe Coatings Introduction and Business Overview
7.25.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.25.4 NanoSafe Coatings Antibacterial (Drug) Resistance Product Offerings
7.25.5 NanoSafe Coatings Recent Development
7.26 Novexel
7.26.1 Novexel Company Information
7.26.2 Novexel Introduction and Business Overview
7.26.3 Novexel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.26.4 Novexel Antibacterial (Drug) Resistance Product Offerings
7.26.5 Novexel Recent Development
7.27 Osel
7.27.1 Osel Company Information
7.27.2 Osel Introduction and Business Overview
7.27.3 Osel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.27.4 Osel Antibacterial (Drug) Resistance Product Offerings
7.27.5 Osel Recent Development
7.28 VenatoRx Pharmaceuticals
7.28.1 VenatoRx Pharmaceuticals Company Information
7.28.2 VenatoRx Pharmaceuticals Introduction and Business Overview
7.28.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.28.4 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Offerings
7.28.5 VenatoRx Pharmaceuticals Recent Development
7.29 AAIPharma Services
7.29.1 AAIPharma Services Company Information
7.29.2 AAIPharma Services Introduction and Business Overview
7.29.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.29.4 AAIPharma Services Antibacterial (Drug) Resistance Product Offerings
7.29.5 AAIPharma Services Recent Development
7.30 ANTABIO
7.30.1 ANTABIO Company Information
7.30.2 ANTABIO Introduction and Business Overview
7.30.3 ANTABIO Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.30.4 ANTABIO Antibacterial (Drug) Resistance Product Offerings
7.30.5 ANTABIO Recent Development
8 Industry Chain Analysis
8.1 Antibacterial (Drug) Resistance Industrial Chain
8.2 Antibacterial (Drug) Resistance Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Antibacterial (Drug) Resistance Sales Model
8.5.2 Sales Channel
8.5.3 Antibacterial (Drug) Resistance Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Antibacterial (Drug) Resistance Product Introduction
1.2 Global Antibacterial (Drug) Resistance Market Size Forecast
1.2.1 Global Antibacterial (Drug) Resistance Sales Value (2019-2030)
1.2.2 Global Antibacterial (Drug) Resistance Sales Volume (2019-2030)
1.2.3 Global Antibacterial (Drug) Resistance Sales Price (2019-2030)
1.3 Antibacterial (Drug) Resistance Market Trends & Drivers
1.3.1 Antibacterial (Drug) Resistance Industry Trends
1.3.2 Antibacterial (Drug) Resistance Market Drivers & Opportunity
1.3.3 Antibacterial (Drug) Resistance Market Challenges
1.3.4 Antibacterial (Drug) Resistance Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Antibacterial (Drug) Resistance Players Revenue Ranking (2023)
2.2 Global Antibacterial (Drug) Resistance Revenue by Company (2019-2024)
2.3 Global Antibacterial (Drug) Resistance Players Sales Volume Ranking (2023)
2.4 Global Antibacterial (Drug) Resistance Sales Volume by Company Players (2019-2024)
2.5 Global Antibacterial (Drug) Resistance Average Price by Company (2019-2024)
2.6 Key Manufacturers Antibacterial (Drug) Resistance Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Antibacterial (Drug) Resistance Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Antibacterial (Drug) Resistance
2.9 Antibacterial (Drug) Resistance Market Competitive Analysis
2.9.1 Antibacterial (Drug) Resistance Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Antibacterial (Drug) Resistance Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibacterial (Drug) Resistance as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Telavancin (Vibativ)
3.1.2 Ceftaroline Fosamil (Teflaro/ Zinforo)
3.1.3 Fidaxomicin (Dificid / Dificlir)
3.1.4 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
3.1.5 Dalbavancin (Dalvance/ Xydalba)
3.1.6 Tedizolid Phosphate (Sivextro)
3.1.7 Oritavancin (Orbactiv/ Nuvocid)
3.1.8 Ceftolozane-Tazobactam (Zerbaxa)
3.1.9 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
3.1.10 PHASE III DRUGS
3.2 Global Antibacterial (Drug) Resistance Sales Value by Type
3.2.1 Global Antibacterial (Drug) Resistance Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Antibacterial (Drug) Resistance Sales Value, by Type (2019-2030)
3.2.3 Global Antibacterial (Drug) Resistance Sales Value, by Type (%) (2019-2030)
3.3 Global Antibacterial (Drug) Resistance Sales Volume by Type
3.3.1 Global Antibacterial (Drug) Resistance Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Antibacterial (Drug) Resistance Sales Volume, by Type (2019-2030)
3.3.3 Global Antibacterial (Drug) Resistance Sales Volume, by Type (%) (2019-2030)
3.4 Global Antibacterial (Drug) Resistance Average Price by Type (2019-2030)
4 Segmentation by Indication
4.1 Introduction by Indication
4.1.1 Complicated Urinary Tract Infection (CUTI)
4.1.2 Complicated Intra-Abdominal Infections (CIAI)
4.1.3 Blood Stream Infections (BSI)
4.1.4 Clostridium Difficile Infections (CDI)
4.1.5 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
4.1.6 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
4.1.7 Community Acquired Bacterial Pneumonia (CABP)
4.2 Global Antibacterial (Drug) Resistance Sales Value by Indication
4.2.1 Global Antibacterial (Drug) Resistance Sales Value by Indication (2019 VS 2023 VS 2030)
4.2.2 Global Antibacterial (Drug) Resistance Sales Value, by Indication (2019-2030)
4.2.3 Global Antibacterial (Drug) Resistance Sales Value, by Indication (%) (2019-2030)
4.3 Global Antibacterial (Drug) Resistance Sales Volume by Indication
4.3.1 Global Antibacterial (Drug) Resistance Sales Volume by Indication (2019 VS 2023 VS 2030)
4.3.2 Global Antibacterial (Drug) Resistance Sales Volume, by Indication (2019-2030)
4.3.3 Global Antibacterial (Drug) Resistance Sales Volume, by Indication (%) (2019-2030)
4.4 Global Antibacterial (Drug) Resistance Average Price by Indication (2019-2030)
5 Segmentation by Region
5.1 Global Antibacterial (Drug) Resistance Sales Value by Region
5.1.1 Global Antibacterial (Drug) Resistance Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Antibacterial (Drug) Resistance Sales Value by Region (2019-2024)
5.1.3 Global Antibacterial (Drug) Resistance Sales Value by Region (2025-2030)
5.1.4 Global Antibacterial (Drug) Resistance Sales Value by Region (%), (2019-2030)
5.2 Global Antibacterial (Drug) Resistance Sales Volume by Region
5.2.1 Global Antibacterial (Drug) Resistance Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Antibacterial (Drug) Resistance Sales Volume by Region (2019-2024)
5.2.3 Global Antibacterial (Drug) Resistance Sales Volume by Region (2025-2030)
5.2.4 Global Antibacterial (Drug) Resistance Sales Volume by Region (%), (2019-2030)
5.3 Global Antibacterial (Drug) Resistance Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Antibacterial (Drug) Resistance Sales Value, 2019-2030
5.4.2 North America Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Antibacterial (Drug) Resistance Sales Value, 2019-2030
5.5.2 Europe Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Antibacterial (Drug) Resistance Sales Value, 2019-2030
5.6.2 Asia Pacific Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Antibacterial (Drug) Resistance Sales Value, 2019-2030
5.7.2 South America Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Antibacterial (Drug) Resistance Sales Value, 2019-2030
5.8.2 Middle East & Africa Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Antibacterial (Drug) Resistance Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Antibacterial (Drug) Resistance Sales Value
6.2.1 Key Countries/Regions Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.2.2 Key Countries/Regions Antibacterial (Drug) Resistance Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.3.2 United States Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
6.4 Europe
6.4.1 Europe Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.4.2 Europe Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
6.5 China
6.5.1 China Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.5.2 China Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.5.3 China Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
6.6 Japan
6.6.1 Japan Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.6.2 Japan Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.7.2 South Korea Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.8.2 Southeast Asia Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
6.9 India
6.9.1 India Antibacterial (Drug) Resistance Sales Value, 2019-2030
6.9.2 India Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
6.9.3 India Antibacterial (Drug) Resistance Sales Value by Indication, 2023 VS 2030
7 Company Profiles
7.1 Melinta Therapeutics
7.1.1 Melinta Therapeutics Company Information
7.1.2 Melinta Therapeutics Introduction and Business Overview
7.1.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Melinta Therapeutics Antibacterial (Drug) Resistance Product Offerings
7.1.5 Melinta Therapeutics Recent Development
7.2 Allergan
7.2.1 Allergan Company Information
7.2.2 Allergan Introduction and Business Overview
7.2.3 Allergan Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Allergan Antibacterial (Drug) Resistance Product Offerings
7.2.5 Allergan Recent Development
7.3 Merck
7.3.1 Merck Company Information
7.3.2 Merck Introduction and Business Overview
7.3.3 Merck Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Merck Antibacterial (Drug) Resistance Product Offerings
7.3.5 Merck Recent Development
7.4 Abbott Laboratories
7.4.1 Abbott Laboratories Company Information
7.4.2 Abbott Laboratories Introduction and Business Overview
7.4.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Abbott Laboratories Antibacterial (Drug) Resistance Product Offerings
7.4.5 Abbott Laboratories Recent Development
7.5 Pfizer
7.5.1 Pfizer Company Information
7.5.2 Pfizer Introduction and Business Overview
7.5.3 Pfizer Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Pfizer Antibacterial (Drug) Resistance Product Offerings
7.5.5 Pfizer Recent Development
7.6 GSK
7.6.1 GSK Company Information
7.6.2 GSK Introduction and Business Overview
7.6.3 GSK Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.6.4 GSK Antibacterial (Drug) Resistance Product Offerings
7.6.5 GSK Recent Development
7.7 PENDOPHARM
7.7.1 PENDOPHARM Company Information
7.7.2 PENDOPHARM Introduction and Business Overview
7.7.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.7.4 PENDOPHARM Antibacterial (Drug) Resistance Product Offerings
7.7.5 PENDOPHARM Recent Development
7.8 Absynth Biologics
7.8.1 Absynth Biologics Company Information
7.8.2 Absynth Biologics Introduction and Business Overview
7.8.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Absynth Biologics Antibacterial (Drug) Resistance Product Offerings
7.8.5 Absynth Biologics Recent Development
7.9 Achaogen
7.9.1 Achaogen Company Information
7.9.2 Achaogen Introduction and Business Overview
7.9.3 Achaogen Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Achaogen Antibacterial (Drug) Resistance Product Offerings
7.9.5 Achaogen Recent Development
7.10 Acino Holdings
7.10.1 Acino Holdings Company Information
7.10.2 Acino Holdings Introduction and Business Overview
7.10.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Acino Holdings Antibacterial (Drug) Resistance Product Offerings
7.10.5 Acino Holdings Recent Development
7.11 Aventis Pharma
7.11.1 Aventis Pharma Company Information
7.11.2 Aventis Pharma Introduction and Business Overview
7.11.3 Aventis Pharma Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Aventis Pharma Antibacterial (Drug) Resistance Product Offerings
7.11.5 Aventis Pharma Recent Development
7.12 Austell Laboratories
7.12.1 Austell Laboratories Company Information
7.12.2 Austell Laboratories Introduction and Business Overview
7.12.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Austell Laboratories Antibacterial (Drug) Resistance Product Offerings
7.12.5 Austell Laboratories Recent Development
7.13 Assembly Biosciences
7.13.1 Assembly Biosciences Company Information
7.13.2 Assembly Biosciences Introduction and Business Overview
7.13.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Assembly Biosciences Antibacterial (Drug) Resistance Product Offerings
7.13.5 Assembly Biosciences Recent Development
7.14 Arpida
7.14.1 Arpida Company Information
7.14.2 Arpida Introduction and Business Overview
7.14.3 Arpida Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Arpida Antibacterial (Drug) Resistance Product Offerings
7.14.5 Arpida Recent Development
7.15 Demuris
7.15.1 Demuris Company Information
7.15.2 Demuris Introduction and Business Overview
7.15.3 Demuris Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Demuris Antibacterial (Drug) Resistance Product Offerings
7.15.5 Demuris Recent Development
7.16 Evolva Holding
7.16.1 Evolva Holding Company Information
7.16.2 Evolva Holding Introduction and Business Overview
7.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Evolva Holding Antibacterial (Drug) Resistance Product Offerings
7.16.5 Evolva Holding Recent Development
7.17 ContraFect
7.17.1 ContraFect Company Information
7.17.2 ContraFect Introduction and Business Overview
7.17.3 ContraFect Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.17.4 ContraFect Antibacterial (Drug) Resistance Product Offerings
7.17.5 ContraFect Recent Development
7.18 Cerexa
7.18.1 Cerexa Company Information
7.18.2 Cerexa Introduction and Business Overview
7.18.3 Cerexa Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Cerexa Antibacterial (Drug) Resistance Product Offerings
7.18.5 Cerexa Recent Development
7.19 InterMune
7.19.1 InterMune Company Information
7.19.2 InterMune Introduction and Business Overview
7.19.3 InterMune Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.19.4 InterMune Antibacterial (Drug) Resistance Product Offerings
7.19.5 InterMune Recent Development
7.20 Isis Pharmaceuticals
7.20.1 Isis Pharmaceuticals Company Information
7.20.2 Isis Pharmaceuticals Introduction and Business Overview
7.20.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.20.4 Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Offerings
7.20.5 Isis Pharmaceuticals Recent Development
7.21 Lyndra
7.21.1 Lyndra Company Information
7.21.2 Lyndra Introduction and Business Overview
7.21.3 Lyndra Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.21.4 Lyndra Antibacterial (Drug) Resistance Product Offerings
7.21.5 Lyndra Recent Development
7.22 Microbecide
7.22.1 Microbecide Company Information
7.22.2 Microbecide Introduction and Business Overview
7.22.3 Microbecide Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.22.4 Microbecide Antibacterial (Drug) Resistance Product Offerings
7.22.5 Microbecide Recent Development
7.23 Morphochem
7.23.1 Morphochem Company Information
7.23.2 Morphochem Introduction and Business Overview
7.23.3 Morphochem Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.23.4 Morphochem Antibacterial (Drug) Resistance Product Offerings
7.23.5 Morphochem Recent Development
7.24 Nabriva Therapeutics
7.24.1 Nabriva Therapeutics Company Information
7.24.2 Nabriva Therapeutics Introduction and Business Overview
7.24.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.24.4 Nabriva Therapeutics Antibacterial (Drug) Resistance Product Offerings
7.24.5 Nabriva Therapeutics Recent Development
7.25 NanoSafe Coatings
7.25.1 NanoSafe Coatings Company Information
7.25.2 NanoSafe Coatings Introduction and Business Overview
7.25.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.25.4 NanoSafe Coatings Antibacterial (Drug) Resistance Product Offerings
7.25.5 NanoSafe Coatings Recent Development
7.26 Novexel
7.26.1 Novexel Company Information
7.26.2 Novexel Introduction and Business Overview
7.26.3 Novexel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.26.4 Novexel Antibacterial (Drug) Resistance Product Offerings
7.26.5 Novexel Recent Development
7.27 Osel
7.27.1 Osel Company Information
7.27.2 Osel Introduction and Business Overview
7.27.3 Osel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.27.4 Osel Antibacterial (Drug) Resistance Product Offerings
7.27.5 Osel Recent Development
7.28 VenatoRx Pharmaceuticals
7.28.1 VenatoRx Pharmaceuticals Company Information
7.28.2 VenatoRx Pharmaceuticals Introduction and Business Overview
7.28.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.28.4 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Offerings
7.28.5 VenatoRx Pharmaceuticals Recent Development
7.29 AAIPharma Services
7.29.1 AAIPharma Services Company Information
7.29.2 AAIPharma Services Introduction and Business Overview
7.29.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.29.4 AAIPharma Services Antibacterial (Drug) Resistance Product Offerings
7.29.5 AAIPharma Services Recent Development
7.30 ANTABIO
7.30.1 ANTABIO Company Information
7.30.2 ANTABIO Introduction and Business Overview
7.30.3 ANTABIO Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2019-2024)
7.30.4 ANTABIO Antibacterial (Drug) Resistance Product Offerings
7.30.5 ANTABIO Recent Development
8 Industry Chain Analysis
8.1 Antibacterial (Drug) Resistance Industrial Chain
8.2 Antibacterial (Drug) Resistance Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Antibacterial (Drug) Resistance Sales Model
8.5.2 Sales Channel
8.5.3 Antibacterial (Drug) Resistance Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Antibacterial (Drug) Resistance Market Trends
Table 2. Antibacterial (Drug) Resistance Market Drivers & Opportunity
Table 3. Antibacterial (Drug) Resistance Market Challenges
Table 4. Antibacterial (Drug) Resistance Market Restraints
Table 5. Global Antibacterial (Drug) Resistance Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Antibacterial (Drug) Resistance Revenue Market Share by Company (2019-2024)
Table 7. Global Antibacterial (Drug) Resistance Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Antibacterial (Drug) Resistance Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Antibacterial (Drug) Resistance Price by Company (2019-2024) & (USD/Unit)
Table 10. Key Manufacturers Antibacterial (Drug) Resistance Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Antibacterial (Drug) Resistance Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Antibacterial (Drug) Resistance
Table 13. Global Antibacterial (Drug) Resistance Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibacterial (Drug) Resistance as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Antibacterial (Drug) Resistance Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Antibacterial (Drug) Resistance Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Antibacterial (Drug) Resistance Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Antibacterial (Drug) Resistance Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Antibacterial (Drug) Resistance Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Antibacterial (Drug) Resistance Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Antibacterial (Drug) Resistance Price by Type (2019-2024) & (USD/Unit)
Table 27. Global Antibacterial (Drug) Resistance Price by Type (2025-2030) & (USD/Unit)
Table 28. Global Antibacterial (Drug) Resistance Sales Value by Indication: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Antibacterial (Drug) Resistance Sales Value by Indication (2019-2024) & (US$ Million)
Table 30. Global Antibacterial (Drug) Resistance Sales Value by Indication (2025-2030) & (US$ Million)
Table 31. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Indication (2019-2024) & (%)
Table 32. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Indication (2025-2030) & (%)
Table 33. Global Antibacterial (Drug) Resistance Sales Volume by Indication: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Antibacterial (Drug) Resistance Sales Volume by Indication (2019-2024) & (K Units)
Table 35. Global Antibacterial (Drug) Resistance Sales Volume by Indication (2025-2030) & (K Units)
Table 36. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Indication (2019-2024) & (%)
Table 37. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Indication (2025-2030) & (%)
Table 38. Global Antibacterial (Drug) Resistance Price by Indication (2019-2024) & (USD/Unit)
Table 39. Global Antibacterial (Drug) Resistance Price by Indication (2025-2030) & (USD/Unit)
Table 40. Global Antibacterial (Drug) Resistance Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Antibacterial (Drug) Resistance Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Antibacterial (Drug) Resistance Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Antibacterial (Drug) Resistance Sales Value by Region (2019-2024) & (%)
Table 44. Global Antibacterial (Drug) Resistance Sales Value by Region (2025-2030) & (%)
Table 45. Global Antibacterial (Drug) Resistance Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Antibacterial (Drug) Resistance Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Antibacterial (Drug) Resistance Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Antibacterial (Drug) Resistance Sales Volume by Region (2019-2024) & (%)
Table 49. Global Antibacterial (Drug) Resistance Sales Volume by Region (2025-2030) & (%)
Table 50. Global Antibacterial (Drug) Resistance Average Price by Region (2019-2024) & (USD/Unit)
Table 51. Global Antibacterial (Drug) Resistance Average Price by Region (2025-2030) & (USD/Unit)
Table 52. Key Countries/Regions Antibacterial (Drug) Resistance Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Antibacterial (Drug) Resistance Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Antibacterial (Drug) Resistance Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Antibacterial (Drug) Resistance Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Antibacterial (Drug) Resistance Sales Volume, (2025-2030) & (K Units)
Table 57. Melinta Therapeutics Company Information
Table 58. Melinta Therapeutics Introduction and Business Overview
Table 59. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 60. Melinta Therapeutics Antibacterial (Drug) Resistance Product Offerings
Table 61. Melinta Therapeutics Recent Development
Table 62. Allergan Company Information
Table 63. Allergan Introduction and Business Overview
Table 64. Allergan Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 65. Allergan Antibacterial (Drug) Resistance Product Offerings
Table 66. Allergan Recent Development
Table 67. Merck Company Information
Table 68. Merck Introduction and Business Overview
Table 69. Merck Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 70. Merck Antibacterial (Drug) Resistance Product Offerings
Table 71. Merck Recent Development
Table 72. Abbott Laboratories Company Information
Table 73. Abbott Laboratories Introduction and Business Overview
Table 74. Abbott Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 75. Abbott Laboratories Antibacterial (Drug) Resistance Product Offerings
Table 76. Abbott Laboratories Recent Development
Table 77. Pfizer Company Information
Table 78. Pfizer Introduction and Business Overview
Table 79. Pfizer Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 80. Pfizer Antibacterial (Drug) Resistance Product Offerings
Table 81. Pfizer Recent Development
Table 82. GSK Company Information
Table 83. GSK Introduction and Business Overview
Table 84. GSK Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 85. GSK Antibacterial (Drug) Resistance Product Offerings
Table 86. GSK Recent Development
Table 87. PENDOPHARM Company Information
Table 88. PENDOPHARM Introduction and Business Overview
Table 89. PENDOPHARM Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 90. PENDOPHARM Antibacterial (Drug) Resistance Product Offerings
Table 91. PENDOPHARM Recent Development
Table 92. Absynth Biologics Company Information
Table 93. Absynth Biologics Introduction and Business Overview
Table 94. Absynth Biologics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 95. Absynth Biologics Antibacterial (Drug) Resistance Product Offerings
Table 96. Absynth Biologics Recent Development
Table 97. Achaogen Company Information
Table 98. Achaogen Introduction and Business Overview
Table 99. Achaogen Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 100. Achaogen Antibacterial (Drug) Resistance Product Offerings
Table 101. Achaogen Recent Development
Table 102. Acino Holdings Company Information
Table 103. Acino Holdings Introduction and Business Overview
Table 104. Acino Holdings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 105. Acino Holdings Antibacterial (Drug) Resistance Product Offerings
Table 106. Acino Holdings Recent Development
Table 107. Aventis Pharma Company Information
Table 108. Aventis Pharma Introduction and Business Overview
Table 109. Aventis Pharma Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 110. Aventis Pharma Antibacterial (Drug) Resistance Product Offerings
Table 111. Aventis Pharma Recent Development
Table 112. Austell Laboratories Company Information
Table 113. Austell Laboratories Introduction and Business Overview
Table 114. Austell Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 115. Austell Laboratories Antibacterial (Drug) Resistance Product Offerings
Table 116. Austell Laboratories Recent Development
Table 117. Assembly Biosciences Company Information
Table 118. Assembly Biosciences Introduction and Business Overview
Table 119. Assembly Biosciences Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 120. Assembly Biosciences Antibacterial (Drug) Resistance Product Offerings
Table 121. Assembly Biosciences Recent Development
Table 122. Arpida Company Information
Table 123. Arpida Introduction and Business Overview
Table 124. Arpida Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 125. Arpida Antibacterial (Drug) Resistance Product Offerings
Table 126. Arpida Recent Development
Table 127. Demuris Company Information
Table 128. Demuris Introduction and Business Overview
Table 129. Demuris Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 130. Demuris Antibacterial (Drug) Resistance Product Offerings
Table 131. Demuris Recent Development
Table 132. Evolva Holding Company Information
Table 133. Evolva Holding Introduction and Business Overview
Table 134. Evolva Holding Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 135. Evolva Holding Antibacterial (Drug) Resistance Product Offerings
Table 136. Evolva Holding Recent Development
Table 137. ContraFect Company Information
Table 138. ContraFect Introduction and Business Overview
Table 139. ContraFect Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 140. ContraFect Antibacterial (Drug) Resistance Product Offerings
Table 141. ContraFect Recent Development
Table 142. Cerexa Company Information
Table 143. Cerexa Introduction and Business Overview
Table 144. Cerexa Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 145. Cerexa Antibacterial (Drug) Resistance Product Offerings
Table 146. Cerexa Recent Development
Table 147. InterMune Company Information
Table 148. InterMune Introduction and Business Overview
Table 149. InterMune Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 150. InterMune Antibacterial (Drug) Resistance Product Offerings
Table 151. InterMune Recent Development
Table 152. Isis Pharmaceuticals Company Information
Table 153. Isis Pharmaceuticals Introduction and Business Overview
Table 154. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 155. Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Offerings
Table 156. Isis Pharmaceuticals Recent Development
Table 157. Lyndra Company Information
Table 158. Lyndra Introduction and Business Overview
Table 159. Lyndra Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 160. Lyndra Antibacterial (Drug) Resistance Product Offerings
Table 161. Lyndra Recent Development
Table 162. Microbecide Company Information
Table 163. Microbecide Introduction and Business Overview
Table 164. Microbecide Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 165. Microbecide Antibacterial (Drug) Resistance Product Offerings
Table 166. Microbecide Recent Development
Table 167. Morphochem Company Information
Table 168. Morphochem Introduction and Business Overview
Table 169. Morphochem Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 170. Morphochem Antibacterial (Drug) Resistance Product Offerings
Table 171. Morphochem Recent Development
Table 172. Nabriva Therapeutics Company Information
Table 173. Nabriva Therapeutics Introduction and Business Overview
Table 174. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 175. Nabriva Therapeutics Antibacterial (Drug) Resistance Product Offerings
Table 176. Nabriva Therapeutics Recent Development
Table 177. NanoSafe Coatings Introduction and Business Overview
Table 178. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 179. NanoSafe Coatings Antibacterial (Drug) Resistance Product Offerings
Table 180. NanoSafe Coatings Recent Development
Table 181. NanoSafe Coatings Company Information
Table 182. Novexel Company Information
Table 183. Novexel Introduction and Business Overview
Table 184. Novexel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 185. Novexel Antibacterial (Drug) Resistance Product Offerings
Table 186. Novexel Recent Development
Table 187. Osel Company Information
Table 188. Osel Introduction and Business Overview
Table 189. Osel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 190. Osel Antibacterial (Drug) Resistance Product Offerings
Table 191. Osel Recent Development
Table 192. VenatoRx Pharmaceuticals Company Information
Table 193. VenatoRx Pharmaceuticals Introduction and Business Overview
Table 194. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 195. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Offerings
Table 196. VenatoRx Pharmaceuticals Recent Development
Table 197. AAIPharma Services Company Information
Table 198. AAIPharma Services Introduction and Business Overview
Table 199. AAIPharma Services Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 200. AAIPharma Services Antibacterial (Drug) Resistance Product Offerings
Table 201. AAIPharma Services Recent Development
Table 202. ANTABIO Company Information
Table 203. ANTABIO Introduction and Business Overview
Table 204. ANTABIO Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 205. ANTABIO Antibacterial (Drug) Resistance Product Offerings
Table 206. ANTABIO Recent Development
Table 207. Key Raw Materials Lists
Table 208. Raw Materials Key Suppliers Lists
Table 209. Antibacterial (Drug) Resistance Downstream Customers
Table 210. Antibacterial (Drug) Resistance Distributors List
Table 211. Research Programs/Design for This Report
Table 212. Key Data Information from Secondary Sources
Table 213. Key Data Information from Primary Sources
List of Figures
Figure 1. Antibacterial (Drug) Resistance Product Picture
Figure 2. Global Antibacterial (Drug) Resistance Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Antibacterial (Drug) Resistance Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Antibacterial (Drug) Resistance Sales Volume (2019-2030) & (K Units)
Figure 5. Global Antibacterial (Drug) Resistance Sales Price (2019-2030) & (USD/Unit)
Figure 6. Antibacterial (Drug) Resistance Report Years Considered
Figure 7. Global Antibacterial (Drug) Resistance Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Antibacterial (Drug) Resistance Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Antibacterial (Drug) Resistance Revenue in 2023
Figure 10. Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Telavancin (Vibativ) Picture
Figure 12. Ceftaroline Fosamil (Teflaro/ Zinforo) Picture
Figure 13. Fidaxomicin (Dificid / Dificlir) Picture
Figure 14. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Picture
Figure 15. Dalbavancin (Dalvance/ Xydalba) Picture
Figure 16. Tedizolid Phosphate (Sivextro) Picture
Figure 17. Oritavancin (Orbactiv/ Nuvocid) Picture
Figure 18. Ceftolozane-Tazobactam (Zerbaxa) Picture
Figure 19. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Picture
Figure 20. PHASE III DRUGS Picture
Figure 21. Global Antibacterial (Drug) Resistance Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Antibacterial (Drug) Resistance Sales Value Market Share by Type, 2023 & 2030
Figure 23. Global Antibacterial (Drug) Resistance Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 24. Global Antibacterial (Drug) Resistance Sales Volume Market Share by Type, 2023 & 2030
Figure 25. Global Antibacterial (Drug) Resistance Price by Type (2019-2030) & (USD/Unit)
Figure 26. Product Picture of Complicated Urinary Tract Infection (CUTI)
Figure 27. Product Picture of Complicated Intra-Abdominal Infections (CIAI)
Figure 28. Product Picture of Blood Stream Infections (BSI)
Figure 29. Product Picture of Clostridium Difficile Infections (CDI)
Figure 30. Product Picture of Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Figure 31. Product Picture of Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Figure 32. Product Picture of Community Acquired Bacterial Pneumonia (CABP)
Figure 33. Global Antibacterial (Drug) Resistance Sales Value by Indication (2019 VS 2023 VS 2030) & (US$ Million)
Figure 34. Global Antibacterial (Drug) Resistance Sales Value Market Share by Indication, 2023 & 2030
Figure 35. Global Antibacterial (Drug) Resistance Sales Volume by Indication (2019 VS 2023 VS 2030) & (K Units)
Figure 36. Global Antibacterial (Drug) Resistance Sales Volume Market Share by Indication, 2023 & 2030
Figure 37. Global Antibacterial (Drug) Resistance Price by Indication (2019-2030) & (USD/Unit)
Figure 38. North America Antibacterial (Drug) Resistance Sales Value (2019-2030) & (US$ Million)
Figure 39. North America Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
Figure 40. Europe Antibacterial (Drug) Resistance Sales Value (2019-2030) & (US$ Million)
Figure 41. Europe Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
Figure 42. Asia Pacific Antibacterial (Drug) Resistance Sales Value (2019-2030) & (US$ Million)
Figure 43. Asia Pacific Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
Figure 44. South America Antibacterial (Drug) Resistance Sales Value (2019-2030) & (US$ Million)
Figure 45. South America Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
Figure 46. Middle East & Africa Antibacterial (Drug) Resistance Sales Value (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
Figure 48. Key Countries/Regions Antibacterial (Drug) Resistance Sales Value (%), (2019-2030)
Figure 49. Key Countries/Regions Antibacterial (Drug) Resistance Sales Volume (%), (2019-2030)
Figure 50. United States Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 51. United States Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 52. United States Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 53. Europe Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 54. Europe Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 55. Europe Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 56. China Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 57. China Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 58. China Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 59. Japan Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 60. Japan Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 61. Japan Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 62. South Korea Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 63. South Korea Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 64. South Korea Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 65. Southeast Asia Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 66. Southeast Asia Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 67. Southeast Asia Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 68. India Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 69. India Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 70. India Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 71. Antibacterial (Drug) Resistance Industrial Chain
Figure 72. Antibacterial (Drug) Resistance Manufacturing Cost Structure
Figure 73. Channels of Distribution (Direct Sales, and Distribution)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
Table 1. Antibacterial (Drug) Resistance Market Trends
Table 2. Antibacterial (Drug) Resistance Market Drivers & Opportunity
Table 3. Antibacterial (Drug) Resistance Market Challenges
Table 4. Antibacterial (Drug) Resistance Market Restraints
Table 5. Global Antibacterial (Drug) Resistance Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Antibacterial (Drug) Resistance Revenue Market Share by Company (2019-2024)
Table 7. Global Antibacterial (Drug) Resistance Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Antibacterial (Drug) Resistance Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Antibacterial (Drug) Resistance Price by Company (2019-2024) & (USD/Unit)
Table 10. Key Manufacturers Antibacterial (Drug) Resistance Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Antibacterial (Drug) Resistance Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Antibacterial (Drug) Resistance
Table 13. Global Antibacterial (Drug) Resistance Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibacterial (Drug) Resistance as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Antibacterial (Drug) Resistance Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Antibacterial (Drug) Resistance Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Antibacterial (Drug) Resistance Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Antibacterial (Drug) Resistance Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Antibacterial (Drug) Resistance Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Antibacterial (Drug) Resistance Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Antibacterial (Drug) Resistance Price by Type (2019-2024) & (USD/Unit)
Table 27. Global Antibacterial (Drug) Resistance Price by Type (2025-2030) & (USD/Unit)
Table 28. Global Antibacterial (Drug) Resistance Sales Value by Indication: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Antibacterial (Drug) Resistance Sales Value by Indication (2019-2024) & (US$ Million)
Table 30. Global Antibacterial (Drug) Resistance Sales Value by Indication (2025-2030) & (US$ Million)
Table 31. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Indication (2019-2024) & (%)
Table 32. Global Antibacterial (Drug) Resistance Sales Market Share in Value by Indication (2025-2030) & (%)
Table 33. Global Antibacterial (Drug) Resistance Sales Volume by Indication: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Antibacterial (Drug) Resistance Sales Volume by Indication (2019-2024) & (K Units)
Table 35. Global Antibacterial (Drug) Resistance Sales Volume by Indication (2025-2030) & (K Units)
Table 36. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Indication (2019-2024) & (%)
Table 37. Global Antibacterial (Drug) Resistance Sales Market Share in Volume by Indication (2025-2030) & (%)
Table 38. Global Antibacterial (Drug) Resistance Price by Indication (2019-2024) & (USD/Unit)
Table 39. Global Antibacterial (Drug) Resistance Price by Indication (2025-2030) & (USD/Unit)
Table 40. Global Antibacterial (Drug) Resistance Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Antibacterial (Drug) Resistance Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Antibacterial (Drug) Resistance Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Antibacterial (Drug) Resistance Sales Value by Region (2019-2024) & (%)
Table 44. Global Antibacterial (Drug) Resistance Sales Value by Region (2025-2030) & (%)
Table 45. Global Antibacterial (Drug) Resistance Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Antibacterial (Drug) Resistance Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Antibacterial (Drug) Resistance Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Antibacterial (Drug) Resistance Sales Volume by Region (2019-2024) & (%)
Table 49. Global Antibacterial (Drug) Resistance Sales Volume by Region (2025-2030) & (%)
Table 50. Global Antibacterial (Drug) Resistance Average Price by Region (2019-2024) & (USD/Unit)
Table 51. Global Antibacterial (Drug) Resistance Average Price by Region (2025-2030) & (USD/Unit)
Table 52. Key Countries/Regions Antibacterial (Drug) Resistance Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Antibacterial (Drug) Resistance Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Antibacterial (Drug) Resistance Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Antibacterial (Drug) Resistance Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Antibacterial (Drug) Resistance Sales Volume, (2025-2030) & (K Units)
Table 57. Melinta Therapeutics Company Information
Table 58. Melinta Therapeutics Introduction and Business Overview
Table 59. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 60. Melinta Therapeutics Antibacterial (Drug) Resistance Product Offerings
Table 61. Melinta Therapeutics Recent Development
Table 62. Allergan Company Information
Table 63. Allergan Introduction and Business Overview
Table 64. Allergan Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 65. Allergan Antibacterial (Drug) Resistance Product Offerings
Table 66. Allergan Recent Development
Table 67. Merck Company Information
Table 68. Merck Introduction and Business Overview
Table 69. Merck Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 70. Merck Antibacterial (Drug) Resistance Product Offerings
Table 71. Merck Recent Development
Table 72. Abbott Laboratories Company Information
Table 73. Abbott Laboratories Introduction and Business Overview
Table 74. Abbott Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 75. Abbott Laboratories Antibacterial (Drug) Resistance Product Offerings
Table 76. Abbott Laboratories Recent Development
Table 77. Pfizer Company Information
Table 78. Pfizer Introduction and Business Overview
Table 79. Pfizer Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 80. Pfizer Antibacterial (Drug) Resistance Product Offerings
Table 81. Pfizer Recent Development
Table 82. GSK Company Information
Table 83. GSK Introduction and Business Overview
Table 84. GSK Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 85. GSK Antibacterial (Drug) Resistance Product Offerings
Table 86. GSK Recent Development
Table 87. PENDOPHARM Company Information
Table 88. PENDOPHARM Introduction and Business Overview
Table 89. PENDOPHARM Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 90. PENDOPHARM Antibacterial (Drug) Resistance Product Offerings
Table 91. PENDOPHARM Recent Development
Table 92. Absynth Biologics Company Information
Table 93. Absynth Biologics Introduction and Business Overview
Table 94. Absynth Biologics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 95. Absynth Biologics Antibacterial (Drug) Resistance Product Offerings
Table 96. Absynth Biologics Recent Development
Table 97. Achaogen Company Information
Table 98. Achaogen Introduction and Business Overview
Table 99. Achaogen Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 100. Achaogen Antibacterial (Drug) Resistance Product Offerings
Table 101. Achaogen Recent Development
Table 102. Acino Holdings Company Information
Table 103. Acino Holdings Introduction and Business Overview
Table 104. Acino Holdings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 105. Acino Holdings Antibacterial (Drug) Resistance Product Offerings
Table 106. Acino Holdings Recent Development
Table 107. Aventis Pharma Company Information
Table 108. Aventis Pharma Introduction and Business Overview
Table 109. Aventis Pharma Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 110. Aventis Pharma Antibacterial (Drug) Resistance Product Offerings
Table 111. Aventis Pharma Recent Development
Table 112. Austell Laboratories Company Information
Table 113. Austell Laboratories Introduction and Business Overview
Table 114. Austell Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 115. Austell Laboratories Antibacterial (Drug) Resistance Product Offerings
Table 116. Austell Laboratories Recent Development
Table 117. Assembly Biosciences Company Information
Table 118. Assembly Biosciences Introduction and Business Overview
Table 119. Assembly Biosciences Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 120. Assembly Biosciences Antibacterial (Drug) Resistance Product Offerings
Table 121. Assembly Biosciences Recent Development
Table 122. Arpida Company Information
Table 123. Arpida Introduction and Business Overview
Table 124. Arpida Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 125. Arpida Antibacterial (Drug) Resistance Product Offerings
Table 126. Arpida Recent Development
Table 127. Demuris Company Information
Table 128. Demuris Introduction and Business Overview
Table 129. Demuris Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 130. Demuris Antibacterial (Drug) Resistance Product Offerings
Table 131. Demuris Recent Development
Table 132. Evolva Holding Company Information
Table 133. Evolva Holding Introduction and Business Overview
Table 134. Evolva Holding Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 135. Evolva Holding Antibacterial (Drug) Resistance Product Offerings
Table 136. Evolva Holding Recent Development
Table 137. ContraFect Company Information
Table 138. ContraFect Introduction and Business Overview
Table 139. ContraFect Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 140. ContraFect Antibacterial (Drug) Resistance Product Offerings
Table 141. ContraFect Recent Development
Table 142. Cerexa Company Information
Table 143. Cerexa Introduction and Business Overview
Table 144. Cerexa Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 145. Cerexa Antibacterial (Drug) Resistance Product Offerings
Table 146. Cerexa Recent Development
Table 147. InterMune Company Information
Table 148. InterMune Introduction and Business Overview
Table 149. InterMune Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 150. InterMune Antibacterial (Drug) Resistance Product Offerings
Table 151. InterMune Recent Development
Table 152. Isis Pharmaceuticals Company Information
Table 153. Isis Pharmaceuticals Introduction and Business Overview
Table 154. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 155. Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Offerings
Table 156. Isis Pharmaceuticals Recent Development
Table 157. Lyndra Company Information
Table 158. Lyndra Introduction and Business Overview
Table 159. Lyndra Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 160. Lyndra Antibacterial (Drug) Resistance Product Offerings
Table 161. Lyndra Recent Development
Table 162. Microbecide Company Information
Table 163. Microbecide Introduction and Business Overview
Table 164. Microbecide Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 165. Microbecide Antibacterial (Drug) Resistance Product Offerings
Table 166. Microbecide Recent Development
Table 167. Morphochem Company Information
Table 168. Morphochem Introduction and Business Overview
Table 169. Morphochem Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 170. Morphochem Antibacterial (Drug) Resistance Product Offerings
Table 171. Morphochem Recent Development
Table 172. Nabriva Therapeutics Company Information
Table 173. Nabriva Therapeutics Introduction and Business Overview
Table 174. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 175. Nabriva Therapeutics Antibacterial (Drug) Resistance Product Offerings
Table 176. Nabriva Therapeutics Recent Development
Table 177. NanoSafe Coatings Introduction and Business Overview
Table 178. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 179. NanoSafe Coatings Antibacterial (Drug) Resistance Product Offerings
Table 180. NanoSafe Coatings Recent Development
Table 181. NanoSafe Coatings Company Information
Table 182. Novexel Company Information
Table 183. Novexel Introduction and Business Overview
Table 184. Novexel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 185. Novexel Antibacterial (Drug) Resistance Product Offerings
Table 186. Novexel Recent Development
Table 187. Osel Company Information
Table 188. Osel Introduction and Business Overview
Table 189. Osel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 190. Osel Antibacterial (Drug) Resistance Product Offerings
Table 191. Osel Recent Development
Table 192. VenatoRx Pharmaceuticals Company Information
Table 193. VenatoRx Pharmaceuticals Introduction and Business Overview
Table 194. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 195. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Offerings
Table 196. VenatoRx Pharmaceuticals Recent Development
Table 197. AAIPharma Services Company Information
Table 198. AAIPharma Services Introduction and Business Overview
Table 199. AAIPharma Services Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 200. AAIPharma Services Antibacterial (Drug) Resistance Product Offerings
Table 201. AAIPharma Services Recent Development
Table 202. ANTABIO Company Information
Table 203. ANTABIO Introduction and Business Overview
Table 204. ANTABIO Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 205. ANTABIO Antibacterial (Drug) Resistance Product Offerings
Table 206. ANTABIO Recent Development
Table 207. Key Raw Materials Lists
Table 208. Raw Materials Key Suppliers Lists
Table 209. Antibacterial (Drug) Resistance Downstream Customers
Table 210. Antibacterial (Drug) Resistance Distributors List
Table 211. Research Programs/Design for This Report
Table 212. Key Data Information from Secondary Sources
Table 213. Key Data Information from Primary Sources
List of Figures
Figure 1. Antibacterial (Drug) Resistance Product Picture
Figure 2. Global Antibacterial (Drug) Resistance Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Antibacterial (Drug) Resistance Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Antibacterial (Drug) Resistance Sales Volume (2019-2030) & (K Units)
Figure 5. Global Antibacterial (Drug) Resistance Sales Price (2019-2030) & (USD/Unit)
Figure 6. Antibacterial (Drug) Resistance Report Years Considered
Figure 7. Global Antibacterial (Drug) Resistance Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Antibacterial (Drug) Resistance Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Antibacterial (Drug) Resistance Revenue in 2023
Figure 10. Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Telavancin (Vibativ) Picture
Figure 12. Ceftaroline Fosamil (Teflaro/ Zinforo) Picture
Figure 13. Fidaxomicin (Dificid / Dificlir) Picture
Figure 14. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Picture
Figure 15. Dalbavancin (Dalvance/ Xydalba) Picture
Figure 16. Tedizolid Phosphate (Sivextro) Picture
Figure 17. Oritavancin (Orbactiv/ Nuvocid) Picture
Figure 18. Ceftolozane-Tazobactam (Zerbaxa) Picture
Figure 19. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Picture
Figure 20. PHASE III DRUGS Picture
Figure 21. Global Antibacterial (Drug) Resistance Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Antibacterial (Drug) Resistance Sales Value Market Share by Type, 2023 & 2030
Figure 23. Global Antibacterial (Drug) Resistance Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 24. Global Antibacterial (Drug) Resistance Sales Volume Market Share by Type, 2023 & 2030
Figure 25. Global Antibacterial (Drug) Resistance Price by Type (2019-2030) & (USD/Unit)
Figure 26. Product Picture of Complicated Urinary Tract Infection (CUTI)
Figure 27. Product Picture of Complicated Intra-Abdominal Infections (CIAI)
Figure 28. Product Picture of Blood Stream Infections (BSI)
Figure 29. Product Picture of Clostridium Difficile Infections (CDI)
Figure 30. Product Picture of Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Figure 31. Product Picture of Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Figure 32. Product Picture of Community Acquired Bacterial Pneumonia (CABP)
Figure 33. Global Antibacterial (Drug) Resistance Sales Value by Indication (2019 VS 2023 VS 2030) & (US$ Million)
Figure 34. Global Antibacterial (Drug) Resistance Sales Value Market Share by Indication, 2023 & 2030
Figure 35. Global Antibacterial (Drug) Resistance Sales Volume by Indication (2019 VS 2023 VS 2030) & (K Units)
Figure 36. Global Antibacterial (Drug) Resistance Sales Volume Market Share by Indication, 2023 & 2030
Figure 37. Global Antibacterial (Drug) Resistance Price by Indication (2019-2030) & (USD/Unit)
Figure 38. North America Antibacterial (Drug) Resistance Sales Value (2019-2030) & (US$ Million)
Figure 39. North America Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
Figure 40. Europe Antibacterial (Drug) Resistance Sales Value (2019-2030) & (US$ Million)
Figure 41. Europe Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
Figure 42. Asia Pacific Antibacterial (Drug) Resistance Sales Value (2019-2030) & (US$ Million)
Figure 43. Asia Pacific Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
Figure 44. South America Antibacterial (Drug) Resistance Sales Value (2019-2030) & (US$ Million)
Figure 45. South America Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
Figure 46. Middle East & Africa Antibacterial (Drug) Resistance Sales Value (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Antibacterial (Drug) Resistance Sales Value by Country (%), 2023 VS 2030
Figure 48. Key Countries/Regions Antibacterial (Drug) Resistance Sales Value (%), (2019-2030)
Figure 49. Key Countries/Regions Antibacterial (Drug) Resistance Sales Volume (%), (2019-2030)
Figure 50. United States Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 51. United States Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 52. United States Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 53. Europe Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 54. Europe Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 55. Europe Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 56. China Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 57. China Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 58. China Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 59. Japan Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 60. Japan Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 61. Japan Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 62. South Korea Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 63. South Korea Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 64. South Korea Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 65. Southeast Asia Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 66. Southeast Asia Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 67. Southeast Asia Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 68. India Antibacterial (Drug) Resistance Sales Value, (2019-2030) & (US$ Million)
Figure 69. India Antibacterial (Drug) Resistance Sales Value by Type (%), 2023 VS 2030
Figure 70. India Antibacterial (Drug) Resistance Sales Value by Indication (%), 2023 VS 2030
Figure 71. Antibacterial (Drug) Resistance Industrial Chain
Figure 72. Antibacterial (Drug) Resistance Manufacturing Cost Structure
Figure 73. Channels of Distribution (Direct Sales, and Distribution)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232